Trials / Active Not Recruiting
Active Not RecruitingNCT04483284
Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients
Exploratory Clinical Study of TACE Combined With Camrelizumab in the Treatment of BCLC Stage B and Stage C Hepatocellular Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.
Detailed description
This is a prospective, single-center and single-arm exploratory clinical study designed to evaluate the efficacy and safety of TACE combined with Camrelizumab in the treatment of patients with BCLC stage B and C hepatocellular carcinoma.Treatment will continue until disease progression or intolerable toxicity or patients withdrawal of consent,and the target sample size is 60 individuals.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TACE combined with Camrelizumab | Camrelizumab(200mg q3w ivgtt) combined with TACE |
| PROCEDURE | TACE plus Camrelizumab | Camrelizumab(200mg q3w ivgtt) combined with TACE |
Timeline
- Start date
- 2020-06-24
- Primary completion
- 2024-12-01
- Completion
- 2025-05-01
- First posted
- 2020-07-23
- Last updated
- 2024-08-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04483284. Inclusion in this directory is not an endorsement.